{"transactions":[{"id":706025,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-20T20:07:38.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":77148,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.\nRemarks:"}],"balance_after":77148,"derivative":{"exercise_price":116.65,"expiration_date":"2036-07-15","underlying":"Common Stock","underlying_shares":77148},"source":{"system":"sec-edgar","filing":"0001536778-26-000009","document":"wk-form4_1784578056.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879169/000153677826000009/wk-form4_1784578056.xml","form_type":"4"}},{"id":706024,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Shares","published_at":"2026-07-20T20:07:38.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":80421,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return (\"TSR\") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will\nvest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return (\"TSR\") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will\nvest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer."}],"balance_after":80421,"derivative":{"expiration_date":"2029-07-16","underlying":"Common Stock","underlying_shares":80421},"source":{"system":"sec-edgar","filing":"0001536778-26-000009","document":"wk-form4_1784578056.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000153677826000009/wk-form4_1784578056.xml","form_type":"4"}},{"id":706023,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-20T20:07:38.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":26807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents award of restricted stock units (\"RSUs\") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Including the July 16, 2026 grant, this includes an aggregate of 178,883 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":183129,"source":{"system":"sec-edgar","filing":"0001536778-26-000009","document":"wk-form4_1784578056.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000153677826000009/wk-form4_1784578056.xml","form_type":"4"}},{"id":714036,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Executive Officer","other_text":"President"}}],"security":"Common Stock","published_at":"2026-07-07T20:09:36.000Z","date":"2026-07-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":4779,"price":116.86,"value":558473.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This includes an aggregate of 152,076 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested."}],"balance_after":156322,"source":{"system":"sec-edgar","filing":"0001536778-26-000007","document":"wk-form4_1783454973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000153677826000007/wk-form4_1783454973.xml","form_type":"4"}},{"id":806320,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Executive Officer","other_text":"President"}}],"security":"Common Stock","published_at":"2026-04-17T20:13:26.000Z","date":"2026-04-15","kind":"exercise","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 15, 2026. The earned shares will vest on July 2, 2026, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive up to 400% of one share of common stock. The number of shares that may be earned and vested is contingent on the achievement of pre-established performance and vesting conditions over a six-year performance period, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2025. Although the Issuer is obligated to issue these earned shares to the Reporting Person, these shares will settle and be delivered to the Reporting Person on June 26, 2028, the third anniversary of the commencement of his employment with the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This includes an aggregate of 161,101 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested."}],"balance_after":161101,"source":{"system":"sec-edgar","filing":"0001536778-26-000004","document":"wk-form4_1776456803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000153677826000004/wk-form4_1776456803.xml","form_type":"4"}},{"id":1096674,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Executive Officer","other_text":"President"}}],"security":"Performance Shares","published_at":"2025-07-02T20:40:30.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance share represents the right to receive up to 400% of one share of common stock. The number of shares that may be earned and vested is contingent on the achievement of pre-established performance and vesting conditions over a six-year performance period, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each performance share represents the right to receive up to 400% of one share of common stock. The number of shares that may be earned and vested is contingent on the achievement of pre-established performance and vesting conditions over a six-year performance period, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2025."}],"balance_after":125000,"derivative":{"expiration_date":"2031-07-02","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000879169-25-000067","document":"wk-form4_1751488808.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000067/wk-form4_1751488808.xml","form_type":"4"}},{"id":1096673,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Executive Officer","other_text":"President"}}],"security":"Performance Shares","published_at":"2025-07-02T20:40:30.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":108303,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return (\"TSR\") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return (\"TSR\") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer."}],"balance_after":108303,"derivative":{"expiration_date":"2028-07-02","underlying":"Common Stock","underlying_shares":108303},"source":{"system":"sec-edgar","filing":"0000879169-25-000067","document":"wk-form4_1751488808.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000067/wk-form4_1751488808.xml","form_type":"4"}},{"id":1096672,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Executive Officer","other_text":"President"}}],"security":"Common Stock","published_at":"2025-07-02T20:40:30.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":36101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents award of restricted stock units (\"RSUs\") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the July 2, 2025 aggregate grant of 36,101 shares of common stock."}],"balance_after":36101,"source":{"system":"sec-edgar","filing":"0000879169-25-000067","document":"wk-form4_1751488808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000067/wk-form4_1751488808.xml","form_type":"4"}},{"id":1099652,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Executive Officer","other_text":"President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-06-30T22:48:32.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":110630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The June 26, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years."}],"balance_after":110630,"derivative":{"exercise_price":70.81,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":110630},"source":{"system":"sec-edgar","filing":"0001628280-25-033558","document":"wk-form4_1751323704.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000162828025033558/wk-form4_1751323704.xml","form_type":"4"}},{"id":1278479,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T21:38:33.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0000950170-25-016369","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025016369/ownership.xml","form_type":"4"}},{"id":1572006,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:41.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63065,"price":136.81,"value":8627922.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options vested as to 25% on January 3, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":0,"derivative":{"exercise_price":193.19,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":63065},"source":{"system":"sec-edgar","filing":"0001140361-24-013928","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000114036124013928/form4.xml","form_type":"4"}},{"id":1572005,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-03-18T20:30:41.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38688,"price":330,"value":12767040.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":38688},"source":{"system":"sec-edgar","filing":"0001140361-24-013928","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000114036124013928/form4.xml","form_type":"4"}},{"id":1572004,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-18T20:30:41.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19037,"price":330,"value":6282210.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013928","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000114036124013928/form4.xml","form_type":"4"}},{"id":1572003,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-18T20:30:41.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10342,"price":330,"value":3412860.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."}],"balance_after":19037,"source":{"system":"sec-edgar","filing":"0001140361-24-013928","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000114036124013928/form4.xml","form_type":"4"}},{"id":1640637,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-02-15T21:37:49.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":38688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the annual equity award to the reporting person under the Karuna Therapeutics, Inc. 2019 Stock Option and Incentive Plan. Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock, provided that, at the effective time of the proposed merger transaction among the Issuer, Bristol-Myers Squibb Company and Miramar Merger Sub Inc., this RSU award will convert into a cash award equal to the product of (i) the total number of shares of the Issuer's common stock subject to this RSU award immediately prior to such effective time, and (ii) $330. The RSUs or, after such conversion, the cash award, shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the annual equity award to the reporting person under the Karuna Therapeutics, Inc. 2019 Stock Option and Incentive Plan. Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock, provided that, at the effective time of the proposed merger transaction among the Issuer, Bristol-Myers Squibb Company and Miramar Merger Sub Inc., this RSU award will convert into a cash award equal to the product of (i) the total number of shares of the Issuer's common stock subject to this RSU award immediately prior to such effective time, and (ii) $330. The RSUs or, after such conversion, the cash award, shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the annual equity award to the reporting person under the Karuna Therapeutics, Inc. 2019 Stock Option and Incentive Plan. Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock, provided that, at the effective time of the proposed merger transaction among the Issuer, Bristol-Myers Squibb Company and Miramar Merger Sub Inc., this RSU award will convert into a cash award equal to the product of (i) the total number of shares of the Issuer's common stock subject to this RSU award immediately prior to such effective time, and (ii) $330. The RSUs or, after such conversion, the cash award, shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."}],"balance_after":38688,"derivative":{"underlying":"Common Stock","underlying_shares":38688},"source":{"system":"sec-edgar","filing":"0000950170-24-015952","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000095017024015952/ownership.xml","form_type":"4"}},{"id":1651294,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T21:04:17.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001562180-24-001217","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218024001217/primarydocument.xml","form_type":"4"}},{"id":1697764,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-29T21:42:19.000Z","date":"2023-12-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":8694,"price":316.3,"value":2749912.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the partial vesting of restricted stock units previously granted to the Reporting Person on January 3, 2023."}],"balance_after":29379,"source":{"system":"sec-edgar","filing":"0000950170-23-073877","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000095017023073877/ownership.xml","form_type":"4"}},{"id":1815995,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-08-03T13:12:02.000Z","date":"2023-08-02","kind":"exercise","planned":true,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.11,"expiration_date":"2028-09-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001562180-23-006130","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006130/primarydocument.xml","form_type":"4"}},{"id":1815994,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-08-03T13:12:02.000Z","date":"2023-08-02","kind":"exercise","planned":true,"acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.88,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-23-006130","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006130/primarydocument.xml","form_type":"4"}},{"id":1815993,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-08-03T13:12:02.000Z","date":"2023-08-02","kind":"exercise","planned":true,"acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.47,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-23-006130","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006130/primarydocument.xml","form_type":"4"}},{"id":1815992,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T13:12:02.000Z","date":"2023-08-02","kind":"sale","planned":true,"acquired":false,"shares":24000,"price":20.4547,"value":490912.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $20.2950 to $20.89."}],"balance_after":48000,"source":{"system":"sec-edgar","filing":"0001562180-23-006130","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006130/primarydocument.xml","form_type":"4"}},{"id":1815991,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T13:12:02.000Z","date":"2023-08-02","kind":"exercise","planned":true,"acquired":true,"shares":24000,"price":9.47,"value":227280.0,"ownership":{"direct":true},"balance_after":72000,"source":{"system":"sec-edgar","filing":"0001562180-23-006130","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006130/primarydocument.xml","form_type":"4"}},{"id":1815990,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T13:12:02.000Z","date":"2023-08-02","kind":"sale","planned":true,"acquired":false,"shares":24000,"price":20.4563,"value":490951.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $20.30 to $20.97."}],"balance_after":48000,"source":{"system":"sec-edgar","filing":"0001562180-23-006130","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006130/primarydocument.xml","form_type":"4"}},{"id":1815989,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T13:12:02.000Z","date":"2023-08-02","kind":"exercise","planned":true,"acquired":true,"shares":24000,"price":7.88,"value":189120.0,"ownership":{"direct":true},"balance_after":72000,"source":{"system":"sec-edgar","filing":"0001562180-23-006130","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006130/primarydocument.xml","form_type":"4"}},{"id":1815988,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T13:12:02.000Z","date":"2023-08-02","kind":"sale","planned":true,"acquired":false,"shares":35000,"price":20.4556,"value":715946.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sale prices ranged from $20.29 to $21.00."}],"balance_after":48000,"source":{"system":"sec-edgar","filing":"0001562180-23-006130","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006130/primarydocument.xml","form_type":"4"}},{"id":1815987,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T13:12:02.000Z","date":"2023-08-02","kind":"exercise","planned":true,"acquired":true,"shares":35000,"price":7.11,"value":248850.0,"ownership":{"direct":true},"balance_after":83000,"source":{"system":"sec-edgar","filing":"0001562180-23-006130","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006130/primarydocument.xml","form_type":"4"}},{"id":2032315,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T21:55:10.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":48000,"source":{"system":"sec-edgar","filing":"0001562180-23-000945","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023000945/primarydocument.xml","form_type":"4"}},{"id":2061804,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-05T21:10:14.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":63065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest on January 3, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":63065,"derivative":{"exercise_price":193.19,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":63065},"source":{"system":"sec-edgar","filing":"0000899243-23-000978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924323000978/doc4.xml","form_type":"4"}},{"id":2061803,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-05T21:10:14.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":38073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Comprised of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on January 3, 2024, subject to continued service through such dates."}],"balance_after":38073,"source":{"system":"sec-edgar","filing":"0000899243-23-000978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924323000978/doc4.xml","form_type":"4"}},{"id":2413089,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-03T22:29:12.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-001070","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022001070/primarydocument.xml","form_type":"4"}},{"id":2876347,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-05T21:18:21.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant.  The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001562180-21-000929","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021000929/primarydocument.xml","form_type":"4"}},{"id":3153992,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Performance Stock Units","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":26506,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":26506},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153991,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":12304,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":196.16,"expiration_date":"2024-05-12","underlying":"Ordinary Shares","underlying_shares":12304},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153990,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":21621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":80.2,"expiration_date":"2023-05-20","underlying":"Ordinary Shares","underlying_shares":21621},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153989,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":10089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":72.07,"expiration_date":"2022-05-06","underlying":"Ordinary Shares","underlying_shares":10089},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153988,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":16081,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":63.51,"expiration_date":"2021-12-04","underlying":"Ordinary Shares","underlying_shares":16081},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153987,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":509,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":196.16,"expiration_date":"2024-05-12","underlying":"Ordinary Shares","underlying_shares":509},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153986,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":1246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":80.2,"expiration_date":"2023-05-20","underlying":"Ordinary Shares","underlying_shares":1246},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153985,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":1387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":72.07,"expiration_date":"2022-05-06","underlying":"Ordinary Shares","underlying_shares":1387},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153984,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":63.51,"expiration_date":"2021-12-04","underlying":"Ordinary Shares","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153983,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":19278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":224,"expiration_date":"2023-05-08","underlying":"Ordinary Shares","underlying_shares":19278},"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153982,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":25201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the disposition of restricted stock units relating to Allergan Shares (\"Allergan RSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3153981,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-05-12T01:39:33.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":7434,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the disposition of ordinary shares (\"Allergan Shares\") of Allergan plc (\"Allergan\") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. (\"AbbVie\"), Venice Subsidiary, LLC (\"Acquirer Sub\") and Allergan (the \"Transaction Agreement\"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the \"Scheme\").  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-012735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000089924320012735/doc4.xml","form_type":"4"}},{"id":3180323,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-04-07T22:29:22.000Z","date":"2020-04-03","kind":"tax_withholding","acquired":false,"shares":855,"price":175.71,"value":150232.05,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc."}],"balance_after":32635,"source":{"system":"sec-edgar","filing":"0001179110-20-004762","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911020004762/edgar.xml","form_type":"4"}},{"id":3226522,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-03-04T19:21:55.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":21667,"price":193.84,"value":4199931.28,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc."}],"balance_after":33490,"source":{"system":"sec-edgar","filing":"0001179110-20-003041","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911020003041/edgar.xml","form_type":"4"}},{"id":3270000,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-14T21:33:30.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24000,"derivative":{"exercise_price":9.47,"exercise_date":"2021-02-12","expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-20-001229","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020001229/primarydocument.xml","form_type":"4"}},{"id":3326646,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-01-02T22:53:58.000Z","date":"2019-12-31","kind":"tax_withholding","acquired":false,"shares":1504,"price":191.17,"value":287519.68,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":11823,"source":{"system":"sec-edgar","filing":"0001179110-20-000045","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911020000045/edgar.xml","form_type":"4"}},{"id":3492455,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-12T13:00:47.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24000,"derivative":{"exercise_price":7.88,"exercise_date":"2020-06-10","expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-19-003491","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218019003491/primarydocument.xml","form_type":"4"}},{"id":3561103,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-04-05T19:16:17.000Z","date":"2019-04-03","kind":"tax_withholding","acquired":false,"shares":871,"price":145.71,"value":126913.41,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":13327,"source":{"system":"sec-edgar","filing":"0001179110-19-004800","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911019004800/edgar.xml","form_type":"4"}},{"id":3707506,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-01-03T20:54:52.000Z","date":"2018-12-31","kind":"tax_withholding","acquired":false,"shares":1531,"price":133.66,"value":204633.46,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":14198,"source":{"system":"sec-edgar","filing":"0001179110-19-000197","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911019000197/edgar.xml","form_type":"4"}},{"id":3806426,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-27T21:42:03.000Z","date":"2018-09-25","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over a three-year period."}],"balance_after":35000,"derivative":{"exercise_price":7.11,"expiration_date":"2028-09-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001562180-18-004049","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218018004049/primarydocument.xml","form_type":"4"}},{"id":3923576,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Non-Qualified Options to Purchase Common Stock","published_at":"2018-05-21T21:21:52.000Z","date":"2018-05-17","kind":"exercise","acquired":false,"shares":19785,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested in five equal installments on December 6, 2011, 2012, 2013, 2014 and 2015."}],"balance_after":0,"derivative":{"exercise_price":68.11,"expiration_date":"2018-12-05","underlying":"Ordinary Shares","underlying_shares":19785},"source":{"system":"sec-edgar","filing":"0001179110-18-007255","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018007255/edgar.xml","form_type":"4"}},{"id":3923575,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Incentive Stock Option","published_at":"2018-05-21T21:21:52.000Z","date":"2018-05-17","kind":"exercise","acquired":false,"shares":1467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested on December 6, 2015."}],"balance_after":0,"derivative":{"exercise_price":68.11,"expiration_date":"2018-12-05","underlying":"Ordinary Shares","underlying_shares":1467},"source":{"system":"sec-edgar","filing":"0001179110-18-007255","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018007255/edgar.xml","form_type":"4"}},{"id":3923574,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-05-21T21:21:52.000Z","date":"2018-05-17","kind":"sale","acquired":false,"shares":24425,"price":154.59,"value":3775860.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale is pursuant to a previously established 10b5-1 Trading Plan dated November 16, 2017 for the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":15729,"source":{"system":"sec-edgar","filing":"0001179110-18-007255","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018007255/edgar.xml","form_type":"4"}},{"id":3923573,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-05-21T21:21:52.000Z","date":"2018-05-17","kind":"exercise","acquired":true,"shares":19785,"price":68.11,"value":1347556.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This exercise is pursuant to a previously established 10b5-1 Trading Plan dated November 16, 2017 for the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":40154,"source":{"system":"sec-edgar","filing":"0001179110-18-007255","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018007255/edgar.xml","form_type":"4"}},{"id":3923572,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-05-21T21:21:52.000Z","date":"2018-05-17","kind":"exercise","acquired":true,"shares":1467,"price":68.11,"value":99917.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This exercise is pursuant to a previously established 10b5-1 Trading Plan dated November 16, 2017 for the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":20369,"source":{"system":"sec-edgar","filing":"0001179110-18-007255","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018007255/edgar.xml","form_type":"4"}},{"id":3968260,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-04-05T22:57:57.000Z","date":"2018-04-03","kind":"tax_withholding","acquired":false,"shares":819,"price":164.74,"value":134922.06,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":18902,"source":{"system":"sec-edgar","filing":"0000903423-18-000200","document":"meuryf4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000090342318000200/meuryf4.xml","form_type":"4"}},{"id":4051243,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Options to Purchase Common Stock","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"exercise","acquired":false,"shares":17381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The option vested in five equal installments on December 7, 2010, 2011, 2012, 2013 and 2014."}],"balance_after":0,"derivative":{"exercise_price":66.2,"expiration_date":"2019-12-06","underlying":"Ordinary Shares","underlying_shares":17381},"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051242,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Incentive Stock Option","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"exercise","acquired":false,"shares":1510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The option vested on December 7, 2014."}],"balance_after":0,"derivative":{"exercise_price":66.2,"expiration_date":"2019-12-06","underlying":"Ordinary Shares","underlying_shares":1510},"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051241,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Options to Purchase Common Stock","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"exercise","acquired":false,"shares":2765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The option vested in five equal installments on December 8, 2009, 2010, 2011, 2012 and 2013."}],"balance_after":0,"derivative":{"exercise_price":51.07,"expiration_date":"2018-12-07","underlying":"Ordinary Shares","underlying_shares":2765},"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051240,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Incentive Stock Option","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"exercise","acquired":false,"shares":1957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vested on December 8, 2013."}],"balance_after":0,"derivative":{"exercise_price":51.07,"expiration_date":"2018-12-07","underlying":"Ordinary Shares","underlying_shares":1957},"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051239,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":13600,"price":165.16,"value":2246176.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.05 to $165.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":19721,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051238,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":2000,"price":164.62,"value":329240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.04 to $165.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":33321,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051237,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":7200,"price":163.04,"value":1173888.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.68 to $163.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":35321,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051236,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":4700,"price":162.22,"value":762434.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.67 to $162.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":42521,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051235,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par vaule $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":1000,"price":161.1,"value":161100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.59 to $161.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":47221,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051234,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":2400,"price":159.82,"value":383568.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.41 to $160.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":48221,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051233,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par vaule $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":1700,"price":158.78,"value":269926.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.30 to $159.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":50621,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051232,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":1200,"price":157.6,"value":189120.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.30 to $158.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":52321,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051231,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":25079,"price":157.18,"value":3941917.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.29 to $157.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":53521,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051230,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"exercise","acquired":true,"shares":17381,"price":66.2,"value":1150622.2,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":78600,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051229,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"exercise","acquired":true,"shares":1510,"price":66.2,"value":99962.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":61219,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051228,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"exercise","acquired":true,"shares":2765,"price":51.07,"value":141208.55,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":59709,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4051227,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-02-16T22:10:19.000Z","date":"2018-02-14","kind":"exercise","acquired":true,"shares":1957,"price":51.07,"value":99943.99,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total number of shares reported has been reduced by 423 due to prior inadvertent over-reporting of shares beneficially owned by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":56944,"source":{"system":"sec-edgar","filing":"0001179110-18-002291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018002291/edgar.xml","form_type":"4"}},{"id":4116817,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-01-02T21:41:51.000Z","date":"2017-12-29","kind":"tax_withholding","acquired":false,"shares":1611,"price":163.58,"value":263527.38,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":55410,"source":{"system":"sec-edgar","filing":"0001179110-18-000120","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911018000120/edgar.xml","form_type":"4"}},{"id":4143921,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Incentive Stock Option","published_at":"2017-12-04T23:21:27.000Z","date":"2017-12-01","kind":"exercise","acquired":false,"shares":2535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested in two equal installments on December 6, 2011 and 2012."}],"balance_after":0,"derivative":{"exercise_price":78.88,"expiration_date":"2017-12-05","underlying":"Ordinary Shares","underlying_shares":2535},"source":{"system":"sec-edgar","filing":"0001179110-17-014859","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017014859/edgar.xml","form_type":"4"}},{"id":4143920,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Options to Purchase Common Stock","published_at":"2017-12-04T23:21:27.000Z","date":"2017-12-01","kind":"exercise","acquired":false,"shares":9272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested in five equal installments on December 6, 2008, 2009, 2010, 2011 and 2012."}],"balance_after":0,"derivative":{"exercise_price":78.88,"expiration_date":"2017-12-05","underlying":"Ordinary Shares","underlying_shares":9272},"source":{"system":"sec-edgar","filing":"0001179110-17-014859","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017014859/edgar.xml","form_type":"4"}},{"id":4143919,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-12-04T23:21:27.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":2535,"price":173.89,"value":440811.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.51to $174.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":57021,"source":{"system":"sec-edgar","filing":"0001179110-17-014859","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017014859/edgar.xml","form_type":"4"}},{"id":4143918,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-12-04T23:21:27.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":9272,"price":173.89,"value":1612308.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.51to $174.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":59556,"source":{"system":"sec-edgar","filing":"0001179110-17-014859","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017014859/edgar.xml","form_type":"4"}},{"id":4143917,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-12-04T23:21:27.000Z","date":"2017-12-01","kind":"exercise","acquired":true,"shares":2535,"price":78.88,"value":199960.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":68828,"source":{"system":"sec-edgar","filing":"0001179110-17-014859","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017014859/edgar.xml","form_type":"4"}},{"id":4143916,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-12-04T23:21:27.000Z","date":"2017-12-01","kind":"exercise","acquired":true,"shares":9272,"price":78.88,"value":731375.36,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":66293,"source":{"system":"sec-edgar","filing":"0001179110-17-014859","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017014859/edgar.xml","form_type":"4"}},{"id":4178330,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance Based Restricted Share Unit","published_at":"2017-10-31T01:24:04.000Z","date":"2017-10-26","kind":"exercise","acquired":false,"shares":9321,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":9321},"source":{"system":"sec-edgar","filing":"0001179110-17-013554","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017013554/edgar.xml","form_type":"4"}},{"id":4178329,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-10-31T01:24:04.000Z","date":"2017-10-26","kind":"exercise","acquired":true,"shares":9321,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":57021,"source":{"system":"sec-edgar","filing":"0001179110-17-013554","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017013554/edgar.xml","form_type":"4"}},{"id":4317779,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-05-16T22:08:35.000Z","date":"2017-05-15","kind":"tax_withholding","acquired":false,"shares":587,"price":228.22,"value":133965.14,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":47700,"source":{"system":"sec-edgar","filing":"0001179110-17-007334","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017007334/edgar.xml","form_type":"4"}},{"id":4359922,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-04-04T20:22:46.000Z","date":"2017-04-03","kind":"grant","acquired":true,"shares":8835,"price":237.68,"value":2099902.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty percent (20%) on April 3, 2018, twenty percent (20%) on April 3, 2019, twenty percent (20%) on April 3, 2020, twenty percent (20%) on April 3, 2021 and twenty percent (20%) on April 3, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":48287,"source":{"system":"sec-edgar","filing":"0001179110-17-005546","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017005546/edgar.xml","form_type":"4"}},{"id":4447965,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2017-02-15T02:13:22.000Z","date":"2016-12-08","kind":"exercise","acquired":false,"shares":11807,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":188.47,"exercise_date":"2016-12-08","expiration_date":"2016-12-08","underlying":"Ordinary Shares","underlying_shares":11807},"source":{"system":"sec-edgar","filing":"0001179110-17-002432","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017002432/edgar.xml","form_type":"4"}},{"id":4447964,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-02-15T02:13:22.000Z","date":"2016-12-08","kind":"tax_withholding","acquired":false,"shares":9414,"price":188.47,"value":1774256.58,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":39452,"source":{"system":"sec-edgar","filing":"0001179110-17-002432","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017002432/edgar.xml","form_type":"4"}},{"id":4447963,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":29594,"kind":"person","name":"Meury William","position":1,"cik":"0001536778","reported_name":"Meury William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-02-15T02:13:22.000Z","date":"2016-12-08","kind":"exercise","acquired":true,"shares":11807,"price":109.12,"value":1288379.84,"ownership":{"direct":true},"balance_after":48866,"source":{"system":"sec-edgar","filing":"0001179110-17-002432","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536778/000117911017002432/edgar.xml","form_type":"4"}}]}